AN OPEN, MULTICENTER, COMPARATIVE-STUDY OF THE EFFICACY AND SAFETY OFAZITHROMYCIN AND CO-AMOXICLAV IN THE TREATMENT OF UPPER AND LOWER RESPIRATORY-TRACT INFECTIONS IN CHILDREN
Dva. Lauvau et al., AN OPEN, MULTICENTER, COMPARATIVE-STUDY OF THE EFFICACY AND SAFETY OFAZITHROMYCIN AND CO-AMOXICLAV IN THE TREATMENT OF UPPER AND LOWER RESPIRATORY-TRACT INFECTIONS IN CHILDREN, Journal of international medical research, 25(5), 1997, pp. 285-295
Citations number
14
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
An open prospective, multicentre, comparative, randomized (2:1) study
was conducted in 481 children diagnosed as having mild-to-moderate low
er respiratory tract infections. The efficacy and safety of azithromyc
in suspension (10 mg/kg), dosed orally once daily for 3 days, was comp
ared with that of co-amoxiclav (10 mg/kg in a 4:1 ratio), dosed orally
three times daily for 5 - 10 days. The proportion of evaluable patien
ts (n = 472) showing a cure or improvement was significantly higher in
the azithromycin group (96.8%) than in the co-amoxiclav group (91%, P
= 0.0199). There were six relapses in both groups, giving an overall
response rate of 95% for azithromycin versus 87.1% for co-amoxiclav (P
= 0.0025). Adverse events were reported in 10% of the patients treate
d with azithromycin, and 11.3% of co-amoxiclav patients. Reported and
counted compliance was significantly better in the azithromycin group.
A 3-day regimen of azithromycin was as effective and as safe as a 5 -
10 day regimen of co-amoxiclav in the treatment of respiratory tract
infections in children, and compliance was improved.